Seeking Alpha

AstraZeneca (AZN) says there were "no reports of opioid withdrawal" that could be attributed to...

AstraZeneca (AZN) says there were "no reports of opioid withdrawal" that could be attributed to its Naloxegol laxative in a fourth Phase III trial. AZN and partner Nektar Therapeutics (NKTR) will use the outcome to obtain decontrol of naloxegol, which is considered a Schedule II controlled substance by the DEA. With the testing demonstrating other "high-level" safety results, AstraZeneca plans to file for FDA and EU approval of Naloxegol in Q3. (PR)
Comments (1)
  • very_thirsty_for_income
    , contributor
    Comments (358) | Send Message
     
    I was wondering how much anticipated AZN revenue could be realized by Naloxegol . It this an exclusively AZN patented drug?

     

    Thanks, Thirsty
    26 Feb 2013, 03:19 PM Reply Like
DJIA (DIA) S&P 500 (SPY)